New quinoxalinone inhibitors targeting secreted phospholipase A2 and α-glucosidase

New quinoxalinone inhibitors targeting secreted phospholipase A2 and α-glucosidase

Elevated blood glucose and increased activities of secreted phospholipase A2 (sPLA2) are strongly linked to coronary heart disease. In this report, our goal was to develop small heterocyclic compound that inhibit sPLA2. The title compounds were also tested against α-glucosidase and α-amylase. This a...

Full description

Bibliographic Details
Main Authors: Fatmah A. S. Alasmary, Fatima S. Alnahdi, Abir Ben Bacha, Amr M. El-Araby, Nadine Moubayed, Ahmed M. Alafeefy, Moustafa E. El-Araby
Format: Article
Language:English
Published: Taylor & Francis Group 2017-01-01
Series:Journal of Enzyme Inhibition and Medicinal Chemistry
Subjects:
Quinoxalinone
coronary heart disease
diabetic complications
phospholipase A2
α-amylase
α-glucosidase
Online Access:http://dx.doi.org/10.1080/14756366.2017.1363743

Internet

http://dx.doi.org/10.1080/14756366.2017.1363743

Similar Items